Form 4: Vigil Neuroscience Director Mary Thistle Receives Repriced Stock Option Awards

Director Mary Thistle of Vigil Neuroscience, Inc. receives repriced stock option awards and new grants under the company's 2021 Stock Option and Incentive Plan.

Summary

• On May 3, 2024, Mary Thistle, a director at Vigil Neuroscience, Inc., received repriced stock option awards and new grants.
• The repricing of existing stock options was approved by the Issuer's Board of Directors, effective May 3, 2024.
• The exercise price of one stock option award was adjusted to $3.03 per share, reflecting the fair market value on the effective date.
• A total of 24,309 shares are associated with the repriced stock option award, vesting in 36 equal monthly installments starting August 27, 2022.
• Another stock option award for 12,155 shares is fully vested and exercisable as of the report date.
• An additional stock option award for 13,928 shares will vest upon the earlier of June 7, 2024, or the next annual meeting of the Issuer's stockholders.
• The repriced stock option award will revert to its original exercise price if exercised during the Retention Period, which ends one year from the effective date or upon certain events.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices, with a neutral sentiment. The repricing could be seen as slightly positive for incentivizing the director, but also potentially concerning if the original options were significantly underwater.

Positives

• The repricing of stock options may incentivize the director to improve company performance.
• The vesting schedule of the stock options aligns the director's interests with the long-term success of the company.
• The retention period on the repriced stock options further encourages long-term commitment.

Risks

• The repricing of stock options could be viewed negatively by shareholders if the original options were already underwater.
• The potential reversion to the original exercise price during the retention period adds complexity to the option terms.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and terms of the stock option awards.

Industry Context

Stock option repricing is a common practice in the biotech industry to retain and incentivize key personnel, especially when a company's stock price has declined.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Biogen and Amgen also utilize stock options as part of their compensation strategy.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the exercise of stock options.
• Employees may be impacted by the incentive structure created by the stock option awards.

Key Dates